Kura Oncology Inc. Common Stock (KURA)
Stock · NASDAQ · Health Care
$9.08as of 10/16/2026
Price chart
Active signals
KURA Signal Track Record
How signals performed across all stocks →What KURA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | -0.8% | 43% | September 18, 2026 |
| Bollinger Band BreakdownActive now | 26 | +7.1% | 54% | July 28, 2026 |
| Bollinger Band Breakout | 24 | -3.4% | 38% | August 17, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -0.4% | 47% | August 7, 2026 |
| Any 20-session window (baseline) | -1.2% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tum…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 260
- Website
- www.kuraoncology.com/
Fundamentals
- 1-day range
- $9.05$9.68
- Market cap
- $823.83M
- P/E (trailing)
- —
- P/E (forward)
- -3.87
- EPS (trailing)
- $-3.36
- Dividend yield
- —
- Beta
- 0.53
- Avg. volume
- 1.82M
How Kura Oncology Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub
Forecasts
13 analyst ratings
Kura Oncology Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- KURAKura Oncology Inc. Common Stock$9.08▼ 6.39%Market cap $823.83MP/E —$7.36$13.9
- MNPRMonopar Therapeutics Inc. Common Stock$69.27▼ 3.52%Market cap $805.29MP/E —$50.07$124.82
- CLYMClimb Bio Inc. Common Stock$9.82▼ 9.99%Market cap $801.68MP/E —$1.64$18.33
- ACRSAclaris Therapeutics Inc. Common Stock$3.28▼ 6.02%Market cap $850.55MP/E —$1.74$6.6
- DRUGBright Minds Biosciences Inc. Common Stock$51.3▼ 5.37%Market cap $792.81MP/E —$68.02$170
- DSGNDesign Therapeutics Inc. Common Stock$10.31▼ 1.62%Market cap $861.75MP/E —$5.28$17.25
- AMPHAmphastar Pharmaceuticals Inc. Common Stock$25.87▼ 2.08%Market cap $873.48MP/E 14.15$16.65$29.52
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KURA Kura Oncology Inc. Common Stock | $823.83M | — | $9.08 | ▼ 6.39% | $7.36$13.9 |
| MNPR Monopar Therapeutics Inc. Common Stock | $805.29M | — | $69.27 | ▼ 3.52% | $50.07$124.82 |
| CLYM Climb Bio Inc. Common Stock | $801.68M | — | $9.82 | ▼ 9.99% | $1.64$18.33 |
| ACRS Aclaris Therapeutics Inc. Common Stock | $850.55M | — | $3.28 | ▼ 6.02% | $1.74$6.6 |
| DRUG Bright Minds Biosciences Inc. Common Stock | $792.81M | — | $51.3 | ▼ 5.37% | $68.02$170 |
| DSGN Design Therapeutics Inc. Common Stock | $861.75M | — | $10.31 | ▼ 1.62% | $5.28$17.25 |
| AMPH Amphastar Pharmaceuticals Inc. Common Stock | $873.48M | 14.15 | $25.87 | ▼ 2.08% | $16.65$29.52 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Caspian Therapeutics, Kura Oncology Plan To Devise Development Strategy For Caspian's KO-7246 Oral Menin Inhibitor Designed For Diabetes And Other Chronic Metabolic Diseasesbenzinga · 10/13/2026
- Kura Oncology Q2 2026 Earnings Call TranscriptBenzinga · 9/17/2026
- Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →- Troy Edward Wilson · August 24, 2026 · Buy100.0K @ $12.39
- Brian T. Powl · August 21, 2026 · Sale4.3K @ $11.89
- Mollie Leoni · June 18, 2026 · Sale84.9K @ $9.82
- Parks Diane L. · June 4, 2026 · Grant35.0K
- VASCONCELLES MICHAEL · June 4, 2026 · Grant35.0K
- Collins Helen Louise · June 4, 2026 · Grant35.0K
- Mary T. Szela · June 4, 2026 · Grant35.0K
- Thomas Malley · June 4, 2026 · Grant35.0K
- Faheem Hasnain · June 4, 2026 · Grant35.0K
- Carol Schafer · June 4, 2026 · Grant35.0K
- Brian T. Powl · May 21, 2026 · Sale10.0K @ $11
- Kathleen Ford · May 19, 2026 · Sale2.3K @ $9.08
- Brian T. Powl · May 19, 2026 · Sale339 @ $9.21
- Teresa Brophy Bair · May 18, 2026 · Sale2.3K @ $9.38
Institutional Ownership
March 31, 2026
- Total shares held
- 82.36M
- Total value held
- $658.67M
- Institutional holders
- 210
- Unknown9.64M
- Unknown8.58M
- Unknown8.45M
- Unknown4.51M
- Unknown3.79M
- Unknown3.74M
- Unknown3.36M
- Unknown2.64M
- Unknown2.12M
- Unknown2.03M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Kura Oncology Secures $50M for Diabetes Menin Inhibitor Project
Kura Oncology announced a $50 million partnership to develop an oral menin inhibitor for diabetes. The company will work with Caspian Therapeutics on KO‑7246, sharing data and a joint development plan. The move expands Kura’s focus beyond oncology into chronic metabolic diseases. The collaboration signals confidence in the drug’s potential for diabetes treatment.
Kura Oncology Secures $50M for Diabetes Menin Inhibitor Project. Kura Oncology announced a $50 million partnership to develop an oral menin inhibitor for diabetes. The company will work with Caspian Therapeutics on KO‑7246, sharing data and a joint development plan. The move expands Kura’s focus beyond oncology into chronic metabolic diseases. The collaboration signals confidence in the drug’s potential for diabetes treatment.